The Global Erectile Dysfunction Drug Market is predicted to register a Compound Annual Growth Rate (CAGR) of 3.5% between the forecast period of 2019 and 2025, with a market value of $2,930 million in 2025.
Erectile Dysfunction (ED) is in the inability to attain or sustain an erection hard and long enough to have sex. It is one of the most common sexual conditions experienced by millions of men across the world, preventing them to make love.
The global ED drug market is driven by factors such as the incidence of the disorder, prevalence, and patent expiration of blockbuster ED drugs.
In addition, the availability of generic ED drugs along with rising number of cases is expected to increase the market growth.
Globally, the incidence of ED is expected to increase from 152 million in 1995 to 322 million by 2025, according to The Massachusetts Male Aging Study (MMAS).
Furthermore, poor adherence to using ED drugs is expected to hamper the growth of the market between 2019 and 2025.
Major drug companies in the market have been involved in developing generic ED drugs, strategic acquisitions, and mergers to sustain their position in the market.
For example, in December 2017, Teva Pharmaceutical Industries Ltd. announced launch of generic Viagra in the United States. Also, in September 2018, Teva launched generic Cialis in the United States.
The Global Erectile Dysfunction Drugs Market segmentation is based on key drugs and regions.
The key ED drugs include Viagra (sildenafil), Cialis (tadalafil), Levitra (vardenafil), Stendra (avanafil), Zydena (udenafil), Vitaros (alprostadil), among others.
The global ED market is also segmented into retail pharmacy, local pharmacy, and online pharmacy.
Viagra is expected to hold a major share in the market, as it has been the most widely-used ED drug since 1998. Cialis is another drug that is expected to be the fastest growing segment as its effect is for much longer period than Viagra. Cialis works up to 36 hours in the body, while Viagra works for about 4 to 6 hours.
By region, the global ED market is divided into the North America, Latin American, Europe, Asia-Pacific, and the Middle East & Africa. The key market players in the global ED drugs market include Pfizer, Bayer, Eli Lily, Apricus Biosciences, Cristalia Produtos Quimicos Farmaceuticos Ltd., Dong-A Pharmaceutical, Meda Pharmaceuticals, S.K. Chemicals, and Teva Pharmaceutical.
